Patents by Inventor Brent L. Iverson
Brent L. Iverson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7446182Abstract: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.Type: GrantFiled: November 5, 2002Date of Patent: November 4, 2008Assignee: Board of Regents, The University of Texas SystemInventors: George Georgiou, Brent L. Iverson, Jennifer A. Maynard
-
Publication number: 20080262204Abstract: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.Type: ApplicationFiled: November 5, 2002Publication date: October 23, 2008Inventors: George Georgiou, Brent L. Iverson, Jennifer A. Maynard
-
Publication number: 20080242558Abstract: The present invention includes a method and composition of storing and preserving biofilms for input and output of high-density information. One form of the present invention is a fabricated biofilm storage device with a biologic material applied to a substrate to form, e.g., a dry thin film stable at room temperature for extended periods of time. Another form of the present invention is a method of fabricating a biofilm storage device in which a biologic material is applied to a substrate under conditions that promote alignment of the biologic material on the substrate. The composition, method, and kit of the present invention have universal application in biologics, magnetics, optics and microelectronics.Type: ApplicationFiled: July 24, 2007Publication date: October 2, 2008Inventors: Angela M. Belcher, Seung-Wuk Lee, Brent L. Iverson, Soo-Kwan Lee
-
Patent number: 7094571Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display.Type: GrantFiled: July 15, 2003Date of Patent: August 22, 2006Assignee: The Board of Regents of The University of Texas SystemInventors: Barrett R. Harvey, George Georgiou, Brent L. Iverson
-
Patent number: 7083945Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides via “display-less” library screening. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in soluble form in the periplasmic space of gram negative bacteria, such as Escherichia coli, and are mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the surface-expression of ligand fusion proteins employed with phage display.Type: GrantFiled: October 27, 2000Date of Patent: August 1, 2006Assignee: The Board of Regents of The University of Texas SystemInventors: Gang Chen, Andrew Hayhurst, Jeffrey G. Thomas, Brent L. Iverson, George Georgiou
-
Patent number: 6916474Abstract: The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection by Bacillus anthracis.Type: GrantFiled: July 15, 2003Date of Patent: July 12, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Barrett R. Harvey, George Georgiou, Brent L. Iverson
-
Publication number: 20040171139Abstract: The present invention includes a method and composition of storing and preserving biofilms for input and output of high-density information. One form of the present invention is a fabricated biofilm storage device with a biologic material applied to a substrate to form, e.g., a dry thin film stable at room temperature for extended periods of time. Another form of the present invention is a method of fabricating a biofilm storage device in which a biologic material is applied to a substrate under conditions that promote alignment of the biologic material on the substrate. The composition, method, and kit of the present invention have universal application in biologics, magnetics, optics and microelectronics.Type: ApplicationFiled: September 24, 2003Publication date: September 2, 2004Inventors: Angela M. Belcher, Seung-Wuk Lee, Brent L. Iverson, Soo-Kwan Lee
-
Publication number: 20040058403Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display.Type: ApplicationFiled: July 15, 2003Publication date: March 25, 2004Inventors: Barrett R. Harvey, George Georgiou, Brent L. Iverson
-
Publication number: 20030100023Abstract: The invention relates to novel competitive immunoassays that are useful in detecting and quantitatively measuring analytes down to the nanomolar range. The invention also includes methods of selecting antibodies from libraries of polypeptides expressed on a cell surface. In conducting immunoassays, anti-analyte antibody molecules are expressed on the surface of a bacterial cell and then used to bind with labeled analyte. Quantitation is performed by competitively displacing the bound labeled analyte with a known amount of analyte and measuring the label. The method is rapid and inexpensive and may be performed with readily available safe labeling reagents such as fluorescent compounds.Type: ApplicationFiled: February 12, 2001Publication date: May 29, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Brent L. Iverson, George Georgiou, Gang Chen
-
Patent number: 6180341Abstract: The present invention combines PCR™ mutagenesis with in vitro transcription/translation and ELISA for the rapid generation and characterization of protein mutants. The PCR™ products are used directly as the template for the in vitro transcription/translation reactions and because no cloning steps are required, the in vitro saturation mutagenesis of one residue can be completed in duplicate within a week by a single investigator. This high throughput enables the saturation mutagenesis of numerous residues of interest, a process that can be described as in vitro scanning saturation mutagenesis. Compositions and methods of use of such a process are described herein.Type: GrantFiled: April 30, 1998Date of Patent: January 30, 2001Assignee: Board of Regents, The Universiry of Texas SystemInventors: Brent L. Iverson, George Georgiou, Elizabeth A. Burks
-
Patent number: 5808059Abstract: The invention relates to the field of polymer- and other matrix-supported sapphyrins. Disclosed are silica gel, glass, resin and other polymer- and matrix-supported sapphyrins and sapphyrin-containing chromatographic and electrophoretic supports.Type: GrantFiled: August 28, 1995Date of Patent: September 15, 1998Assignee: Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5744302Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: May 11, 1995Date of Patent: April 28, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5672490Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: June 2, 1995Date of Patent: September 30, 1997Assignee: The University of Texas Board of RegentsInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5633354Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: March 13, 1996Date of Patent: May 27, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5607924Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.Type: GrantFiled: June 6, 1995Date of Patent: March 4, 1997Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Meredith Wright
-
Patent number: 5594136Abstract: The present invention provides various novel matrix-supported texaphyrins in which a polymeric or solid matrix is covalently modified by the addition of one or more texaphyrins or texaphyrin derivatives. Described are methods of making various polymer-supported texaphyrins, including texaphyrin chromatographic supports, and devices such as catheters, as may be used, for example, in the separation of neutral and anionic species and in applications concerning phosphate ester hydrolysis, other catalytic schemes, MRI, and PDT.Type: GrantFiled: May 3, 1995Date of Patent: January 14, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kr al, Richard E. Thomas, Darren Magda, Daniel A. Smith
-
Patent number: 5565552Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: June 7, 1995Date of Patent: October 15, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5530123Abstract: The present invention provides various covalently modified sapphyrin derivatives and conjugates, and also, polymers including sapphyrin or derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; and polymer supported sapphyrins. Novel sapphyrin dimers, trimers, oligomers and polymers are also described, which polymers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.Type: GrantFiled: October 11, 1994Date of Patent: June 25, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta
-
Patent number: 5457195Abstract: The present invention provides various covalently modified sapphyrin derivatives and conjugates, and also, polymers including sapphyrin or derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; and polymer supported sapphyrins. Novel sapphyrin dimers, trimers, oligomers and polymers are also described, which polymers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.Type: GrantFiled: October 21, 1992Date of Patent: October 10, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta
-
Patent number: 5236825Abstract: A catalytic molecule comprising a receptor molecule containing an antibody combining site that immunologically binds to a plurality of polyvalent metal ion-containing coordination complexes is disclosed. The coordination complex of a first immunoligand is kinetically inert, whereas the coordination complex of a second immunoligand is kinetically labile. The receptor molecule catalyzes a reaction of the second immunoligand. Immunogens, antigens, and methods of making and using the catalytic receptors are disclosed, as are receptor molecules that catalyze the hydrolysis of a predetermined peptide bond.Type: GrantFiled: January 17, 1989Date of Patent: August 17, 1993Assignee: Scripps Clinic and Research FoundationInventors: Brent L. Iverson, Richard A. Lerner